Results 41 to 50 of about 6,454 (219)

Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes:A post hoc analysis from the three-year SURMOUNT-1 trial [PDF]

Aim: We assessed the association between tirzepatide and the 10-year predicted risk of developing cardiovascular disease (CVD) and type 2 diabetes (T2D) among three-year SURMOUNT-1 trial participants. Materials and Methods: This post hoc analysis applied
Dimitriadis, Georgios K, Garvey, W Timothy, Hankosky, Emily R, Jouravskaya, Irina, Lebrec, Jeremie, Lee, Clare J, Stefanski, Adam   +6 more
core   +1 more source

Review of upcoming and currently available anti-obesity drugs in Europe [PDF]

, 2023
Obesity is a chronic metabolic disease currently holding status of an epidemic. Number of patients suffering from this condition has been steadily increasing for over 50 years.
Gryszkiewicz, Patryk, Starownik, Jakub, Szydło, Jakub, Wędrychowski, Jan, Zabielska, Bernadeta   +4 more
core   +1 more source

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

Obesity, EarlyView.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella, Patricia M. Ortega, Víctor Valentí Azcárate, Fernando Rotellar Sastre, Adriana Uriz Pagola, Ahmed Ahmed, Sanjay Purkayastha, Carlota Tuero Ojanguren, Nuria Blanco Asensio, Manuel F. Landecho   +9 more
wiley   +1 more source

Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial

Journal of Diabetes Investigation
Aims/Introduction In the SURPASS J‐mono trial, tirzepatide demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes.
Hanaka Mimura, Tomonori Oura, Rina Chin, Masakazu Takeuchi, Kazuya Fujihara, Hirohito Sone   +5 more
doaj   +1 more source

Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis

Frontiers in Pharmacology
Background: Tirzepatide—a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist—is used to treat type 2 diabetes.
Emiko Otsuka, Emiko Otsuka, Mineaki Kitamura, Mineaki Kitamura, Satoshi Funakoshi, Hiroshi Mukae, Tomoya Nishino   +6 more
doaj   +1 more source

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Obesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays, Phillip Toth, Naim Alkhouri, John Pullman, Bradley Freilich, Joel Neutel, Summer Ji, Scott Stubbe, Parke Hedges, Brian Lian   +9 more
wiley   +1 more source

Tirzepatide’s innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health

Frontiers in Pharmacology
Tirzepatide, a novel GLP-1/GIP dual receptor agonist, shows significant advantages in glycemic management and weight control. By summarizing the results of the SURMOUNT and SURPASS clinical trials, we evaluate the efficacy and safety of tirzepatide in ...
Jingqi Yang, Yuncheng Gu, Huaigang Chen, Huaigang Chen, Hong Wang, Lang Hong, Bin Li, Liu Yang   +7 more
doaj   +1 more source

Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial

Obesity, EarlyView.
ABSTRACT Objective This study compared the effects of phentermine‐topiramate‐ER (mid‐dose 7.5/46 mg) versus placebo on weight loss and cardiovascular disease (CVD) risk outcomes when used as an adjunct to a digitally enhanced lifestyle intervention (DELI).
Alejandro Campos, Wissam Ghusn, Lizeth Cifuentes, Daniel Sacoto, Sima Fansa, Diego Anazco, Maria L. Ricardo‐Silgado, Anas Hashem, Megan Schaefer, William S. Harmsen, Heather J. Gunn, Craig Peterson, Deborah Larsen, Santosh T. Varghese, Maria D. Hurtado, Andres Acosta   +15 more
wiley   +1 more source

Assessing the therapeutic potential of Tirzepatide in modulating inflammatory responses and mitigating acute pancreatitis

Animal Models and Experimental Medicine
Background Acute pancreatitis (AP) is a severe inflammation of the pancreas, marked by elevated enzyme levels, cellular inflammation, and necrosis. Recent studies emphasize the critical role of inflammation in AP progression.
Razan Alawaji, Mohamed S. Abdel‐Bakky, Hussein M. Ali, Miad A. Aljuhani, Abdulaziz Arif A. Alshammari, Hashim K. Kamal, Maamoun M. K. Khoja, Kholoud Alsehemi, Mennatallah A. Korani, Eman S. Said   +9 more
doaj   +1 more source

Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide

JHEP Reports
Background & Aims: In the SYNERGY-NASH trial for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis, tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors ...
Mark L. Hartman, Rohit Loomba, Eric J. Lawitz, Raj Vuppalanchi, Jérôme Boursier, Elisabetta Bugianesi, Masato Yoneda, Yuanyuan Tang, Bram Brouwers, Mathijs C. Bunck, Axel Haupt, Arun J. Sanyal   +11 more
doaj   +1 more source